Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing

British Journal of Clinical Pharmacology

Volumn 81, Issue 3, 2016, Pages 562-568

  Heard, Kennon ^a   Green, Jody L ^b   Anderson, Victoria ^b   Bucher Bartelson, Becki ^b,c   Dart, Richard C ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^c Food Science and Human Nutrition   (United States)

Author keywords

APAP CYS; paracetamol; protein adducts

Indexed keywords

ALANINE AMINOTRANSFERASE; PARACETAMOL; PARACETAMOL PROTEIN ADDUCT; PLACEBO; UNCLASSIFIED DRUG; ACETAMINOPHEN CYSTEINE; ANALGESIC AGENT; BIOLOGICAL MARKER; CYSTEINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GEL FILTRATION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; DOSE RESPONSE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED; ANALGESICS, NON-NARCOTIC; BIOMARKERS; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84959218398     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12831     Document Type: Article

References (17)

1. Bond GR,. Acetaminophen protein adducts: A review. Clin Toxicol 2009; 47: 2-7.
2. Muldrew KL, James LP, Coop L, McCullough SS, Hendrickson HP, Hinson JA, Mayeux PR,. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos 2002; 30: 446-51.
3. Davern TJ 2nd, James LP, Hinson JA, Polson J, Larson AM, Fontana RJ, Lalani E, Munoz S, Shakil AO, Lee WM,. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006; 130: 687-94.
4. James LP, Alonso EM, Hynan LS, Hinson JA, Davern TJ, Lee WM, Squires RH,. Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics 2006; 118: E676-81.
5. James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee WM,. Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos 2009; 37: 1779-84.
6. Khandelwal N, James LP, Sanders C, Larson AM, Lee WM,. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011; 53: 567-76.
7. Heard KJ, Green JL, James LP, Judge BS, Zolot L, Rhyee S, Dart RC,. Acetaminophen-cysteine adducts during therapeutic dosing and following overdose. BMC Gastroenterol 2011; 11: 20.
8. James L, Simpson P, Rahman S, Russo M, Watkins P,. Detection of acetaminophen protein adducts in serum during therapeutic dosing of acetaminophen in healthy volunteers (Abstract). Hepatology 2007; 46: 812A.
9. James LP, Chiew A, Abdel-Rahman SM, Letzig L, Graudins A, Day P, Roberts D,. Acetaminophen protein adduct formation following low-dose acetaminophen exposure: Comparison of immediate-release vs. Extended-release formulations. Eur J Clin Pharmacol 2013; 69: 851-7.
10. Heard K, Green JL, Anderson V, Bucher-Bartelson B, Dart RC,. A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration. BMC Pharmacol Toxicol 2014; 15: 39.
11. McGill MR, Yan HM, Ramachandran A, Murray GJ, Rollins DE, Jaeschke H,. HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 2011; 53: 974-82.
12. Cook SF, King AD, Chang Y, Murray GJ, Norris HR, Dart RC, Green JL, Curry SC, Rollins DE, Wilkins DG,. Quantification of a biomarker of acetaminophen protein adducts in human serum by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry: Clinical and animal model applications. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 985: 131-41.
13. Kim RB, O'Shea D,. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995; 57: 645-55.
14. Thummel KE, Slattery JT, Ro H, Chien JY, Nelson SD, Lown KE, Watkins PB,. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 2000; 67: 591-9.
15. O'Shea D, Davis SN, Kim RB, Wilkinson GR,. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56: 359-67.
16. James LP, Capparelli EV, Simpson PM, Letzig L, Roberts D, Hinson JA, Kearns GL, Blumer JL, Sullivan JE, Network of Pediatric Pharmacology Research Units, National Institutes of Child Health and Human Development. Acetaminophen-associated hepatic injury: Evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther 2008; 84: 684-90.
17. Thulin P, Nordahl G, Gry M, Yimer G, Aklillu E, Makonnen E, Aderaye G, Lindquist L, Mattsson CM, Ekblom B, Antoine DJ, Park BK, Linder S, Harrill AH, Watkins PB, Glinghammar B, Schuppe-Koistinen I,. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int 2014; 34: 367-78.